Saint-Herblain (France), September 18, 2020 – Valneva SE (“Valneva”), a specialized vaccine company focused on preventing diseases with large unmet needs, today announced the retirement of its Chief Financial Officer, David Lawrence, in late 2020.
The Company has initiated a search process with a leading global recruiting agency to identify a new CFO, with the aim of being placed in the first quarter of 2021.
Until the end of the year, David will manage a handover process to ensure a smooth transition with Manfred Tiefenbacher, VP Finance, who will take responsibility for all operational financial matters.
Additionally, David agreed to continue supporting Valneva’s CEO as a consultant in the early part of 2021.
Thomas Lingelbach, managing director of Valneva, said: “We would like to thank David for his great contribution to the Company and its strategic development over the past three years. He has played a vital role in building and executing the Company’s capital formation strategy and, more recently, in our global COVID-19 endeavors, including most notably the wonderful partnership with the UK government. We wish him all the best for his retirement “.
David Lawrence, Chief Financial Officer of Valneva, said: “The last three years with Valneva have been extremely exciting and rewarding. For personal reasons, I decided to retire at the end of the year. I deliver the CFO role with solid financials and a great team. Valneva has great prospects and I can’t wait to see her future successes. “
About Valneva SE
Valneva is a specialized vaccine company focused on preventing diseases with large unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/ JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, the prevention of diarrhea caused by ETEC. The company has several vaccines in development, including unique vaccines against Lyme disease, chikungunya, and COVID-19. Valneva has offices in Austria, Sweden, the United Kingdom, France, Canada and the United States with over 500 employees. For more information visit www.valneva.com and follow the company LinkedIn.
|Valneva Investor and Media Contacts
Investor Relations & Corporate Communications Director
M +33 (0) 6 4516 7099
Valneva Forward-Looking Statements
This press release contains certain forward-looking statements relating to Valneva’s business, including the progress, timing and completion of research, development and clinical trials for candidate products, the ability to manufacture, market, market and gain market acceptance for product candidates, the ability to protect intellectual property and run business without infringing the intellectual property rights of others, estimates for future performance and estimates of anticipated operating losses, future revenue, capital requirements and additional funding requirements . Further, even if Valneva’s actual results or development are consistent with the forward-looking statements contained in this press release, such Valneva’s results or developments may not be indicative of theirs in the future. In some cases, forward-looking statements can be identified with words such as “could”, “should”, “could”, “expect”, “anticipate”, “believe”, “intend”, “estimate”, “goals,” “goals” or similar words. These forward-looking statements are largely based on Valneva’s current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or results to be materially different from any future results, performance or results expressed or implied in these forward-looking statements. In particular, Valneva’s expectations could be influenced, among other things, by uncertainties related to vaccine development and production, unexpected clinical trial results, regulatory actions or unforeseen delays, competition in general, currency fluctuations, impact of the Crisis of European credit and the ability to obtain or maintain the protection of patents or other intellectual property rights. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will actually be realized. Valneva provides the information in these materials as of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.